J&J gets Priority Review designation for nipocalimab BLA
Johnson & Johnson (NYSE:JNJ) has received Priority Review designation from the FDA for the Biologics License Application for ...
EQS-News: Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA)
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...
Johnson & Johnson reports nipocalimab granted FDA Priority Review
Johnson & Johnson announced the nipocalimab Biologics License Application received Priority Review designation from the U.S Food and Drug ...
Hosted on MSN1d
Here's Why You Should Consider Buying Atara Biotherapeutics Stock
Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks ...
Healio5h
Biotech firm to advance novel CAR T-cell therapy for rare, fatal pediatric brain tumor
A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...
Cure Today1d
BLA Has Been Submitted For Kidney Cancer Imaging PET Product Zircaix
A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.
Lost Money on Sangamo Therapeutics, Inc. (SGMO)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo Therapeutics, Inc. ("Sangamo Therapeutics, Inc.") (NASDAQ:SGMO) ...
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Precigen, Inc. (NASDAQ:PGEN) shares are trading higher on Monday after the company completed the rolling submission for a ...
Targeted Oncology7d
FDA Considers Approval of TLX250-CDx in Kidney Cancer
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...
Chime Biologics and Mabgeek advance MG-K10 into Phase III trials
Established in 2022, the partnership is centred on the manufacturing of a cGMP 2000L drug substance commercially.
Johnson & Johnson: Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...
Important Milestone For Biotest: Biologics License Application For Fibrinogen Submitted To The US Food And Drug Administration (FDA)
Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...